Zoetis Inc. $ZTS Shares Acquired by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its stake in Zoetis Inc. by 3.1% during the second quarter, holding 86,814 shares valued at $13.54 million.
• In its latest quarterly earnings, Zoetis reported $1.76 earnings per share, surpassing the consensus estimate by $0.14, and a revenue of $2.46 billion for the quarter.
• Analysts have mixed ratings on Zoetis, with a consensus average target price of $200.88 and five equities research analysts rating it a Buy.

IFM Investors Pty Ltd raised its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 3.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,814 shares of the company's stock after buying an additional 2,603 shares during the quarter. IFM Investors Pty Ltd's holdings in Zoetis were worth $13,539,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Nuveen LLC purchased a new stake in Zoetis in the 1st quarter valued at about $616,375,000. Sarasin & Partners LLP purchased a new stake in shares of Zoetis during the 1st quarter worth about $339,111,000. Mackenzie Financial Corp grew its holdings in shares of Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after purchasing an additional 1,782,110 shares during the period. GAMMA Investing LLC grew its holdings in shares of Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after purchasing an additional 1,747,423 shares during the period. Finally, Polen Capital Management LLC grew its holdings in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Argus reiterated a "buy" rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Stock Down 0.9%

NYSE ZTS traded down $1.28 on Friday, reaching $145.82. The company had a trading volume of 4,455,824 shares, compared to its average volume of 2,273,605. The firm has a market capitalization of $64.63 billion, a PE ratio of 25.10, a P/E/G ratio of 2.34 and a beta of 0.89. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $197.51. The firm has a 50-day moving average of $151.25 and a 200-day moving average of $156.52. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.